Lactobacillus reuteri and application thereof in improving intestinal health of pets

By isolating and identifying the N-FE-002 strain of Lactobacillus mucinous reir, the problem of insufficient development of pet intestinal health probiotics in the prior art was solved, and significant improvements in pet intestinal health were achieved, and good resistance to pet intestinal health was achieved. Pathogenic and safety characteristics.

CN118909835APending Publication Date: 2024-11-08WUHU WEISHI BIOTECHNOLOGY CO LTD +3

Patent Information

Application Number
CN202410967133.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing applications of Lactobacillus reoir are mainly concentrated in the field of human health, with fewer applications for pets, especially fewer probiotics for pet intestinal health, which cannot effectively meet the pet market's demand for pet intestinal health. .

Method used

The strain of Lactobacillus reuteri obtained from feces of healthy juvenile Russian blue cats raised in Tianjin, China was isolated from feces of healthy juvenile Russian blue cats raised in China. It was cultured through MRS plates and identified by 16S rDNA, and was named Limosilactobacillus reuteri, which has good probiotic effects and Safety, used to improve pet gut health. This strain has the effect of inhibiting Shigella dysentery and Clostridium perfringens. It has the characteristics of high acid resistance, bile salt resistance and gastrointestinal fluid resistance. It can enhance the expression of tight junction protein in intestinal cells, reduce the expression of inflammatory factors, and improve the expression of inflammatory factors. Intestinal barrier function.

Benefits of technology

It significantly improves pet intestinal health, enhances intestinal barrier function and reduces inflammatory response by inhibiting the adhesion and invasion of pathogenic bacteria, and has good anti-pathogenic bacterial effects and safety. It is suitable for use as a pet intestinal probiotic.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909835A_ABST
    Figure CN118909835A_ABST
Patent Text Reader

Abstract

The invention discloses lactobacillus reuteri and application thereof in improving intestinal health of pets, and belongs to the technical field of microorganisms. The name of the bacterial strain is N-FE-002, the bacterial strain is derived from excrement of healthy kittens, the bacterial strain is preserved in China General Microbiological Culture Collection Center (CGMCC) in Institute of Microbiology of Chinese Academy of Sciences located in No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing on September 1, 2023, the microbial preservation number of the bacterial strain is CGMCC NO.28325, and the bacterial strain is classified and named as Lactobacillus reuteri. The strain can remarkably improve expression of tight junction protein of intestinal cells, reduce expression of proinflammatory cytokines, enhance the barrier function of the intestinal tract and improve the health of the intestinal tract. The strain can be used for preparing pet food, pet health care products, pet feed additives and pet medicines, and galactooligosaccharide or isomaltooligosaccharide can be further added to enhance the effect of probiotics.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of microorganisms, and in particular relates to a Lactobacillus reuteri N-FE-002 strain and an application thereof. Background Art

[0002] In recent years, with the rapid growth of the pet market, pet owners are paying more and more attention to the health of their pets. As an important part of overall health, intestinal health directly affects the immune function, nutrient absorption and overall vitality of pets. Probiotics, especially Lactobacillus, have received widespread attention due to their unique role in maintaining the balance of intestinal microecology, promoting digestion, enhancing immune function and inhibiting harmful microorganisms. Compared with Lactobacillus from humans or agricultural animals, Lactobacillus from pet intestines has better adaptability and safety, thus better playing its probiotic role. However, most of the probiotics on the market are derived from the intestines of humans or agricultural animals, and there are relatively few probiotics for pets.

[0003] In terms of strain sources, the existing Lactobacillus reuteri strains come from a variety of sources, including human-related samples (such as feces, breast milk, yogurt, etc.) and animal samples (such as yak milk, weaned piglets, cat feces). These strains exhibit significant probiotic functions. For example: Lactobacillus reuteri AUc2301 in patent CN202311600783.2 is derived from cat feces and has anti-inflammatory and immunomodulatory functions. Lactobacillus reuteri DPUL-M94 in patent CN202410105493.9 is not stated, but can metabolize linoleic acid to produce conjugated linoleic acid, enhance intestinal barrier function and anti-inflammatory. Lactobacillus reuteri NAQU LR V in patent CN202410146983.3 is derived from yak milk in Naqu, Tibet, and has the function of inhibiting Helicobacter pylori.

[0004] In terms of application objects and functional uses, most patents are currently applied to humans, mainly focusing on intestinal health, immune regulation, blood pressure regulation, lowering blood sugar, repairing gastrointestinal mucosa, etc. For example: Lactobacillus reuteri GOLDGUT-LR99 in patent CN202410029515.8 is mainly used to relieve human chronic fatigue syndrome, demonstrating its effects in enhancing vitality and immune function. Lactobacillus reuteri DPUL-M94 in patent CN202410105493.9 is mainly used to enhance human intestinal barrier function and anti-inflammatory. Lactobacillus reuteri Glory LR15 in patent CN202410401688.8 is used to improve human immunity. Lactobacillus reuteri DPUL-M94 in patent CN202410105493.9 produces CLA by metabolizing linoleic acid, enhancing human intestinal barrier function and anti-inflammatory. Lactobacillus reuteri AUc2301 in patent CN202311600783.2 has shown significant effects in immunoregulation and anti-inflammatory by regulating immune factors and improving immunity. Lactobacillus reuteri BN01 in patent CN202410263983.1 is used to repair gastrointestinal mucosal damage and improve gastrointestinal function. These strains are mainly used in the field of human health, and there is very little research on their application in pet dogs and cats.

[0005] In summary, Lactobacillus reuteri has broad prospects for application in the health field, especially in improving intestinal health and immune regulation. However, there are few sources and direct applications for pets, and more attention is paid to human health applications. This highlights the importance and necessity of developing probiotics specifically for pets. Summary of the invention

[0006] In view of this, the present invention provides a Lactobacillus reuteri N-FE-002 strain, which is isolated from cat feces, has good probiotic effects and safety, and is used to improve the intestinal health of pets.

[0007] To achieve the above object, the technical solution of the present invention is achieved as follows:

[0008] The strain of the invention is separated from the feces of healthy young Russian blue cats raised by families in Tianjin, China, and a lactic acid strain is obtained by MRS plate culture, separation and purification. The strain is identified as Limosilactobacillus reuteri through 16s rDNA and is named N-FE-002.

[0009] The Lactobacillus reuteri N-FE-002 strain of the present invention was deposited on September 1, 2023 in the China General Microbiological Culture Collection Center (CGMCC) located at the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, China. Its microbial preservation number is CGMCC NO.28325, and its classification name is: Lactobacillus reuteri (Limosilactobacillus reuteri).

[0010] The microbiological characteristics of this strain are: ① Gram staining is positive, and the bacterial morphology is rod-shaped; ② The growth temperature range is 25-45℃, facultative anaerobic, and heterosexual fermentation; ③ It does not produce hemolysin and does not reduce nitrate; ④ It can ferment raffinose, sucrose, maltose, lactose, galactose and starch; it has the ability to produce galactosidase, sucrase, glucosidase and amylase.

[0011] The Lactobacillus reuteri N-FE-002 strain of the present invention is used in improving the intestinal health of pets and has the effect of inhibiting Shigella dysenteriae and Clostridium perfringens.

[0012] The Lactobacillus reuteri N-FE-002 strain described in the present invention is used in improving the intestinal health of pets and has strong intestinal cell adhesion and colonization ability.

[0013] The Lactobacillus reuteri N-FE-002 strain described in the present invention is used in improving the intestinal health of pets and has the effect of resisting the adhesion of pathogenic bacteria to intestinal cells.

[0014] The application of the Lactobacillus reuteri N-FE-002 strain in the present invention in improving the intestinal health of pets has the effect of alleviating the intestinal cell barrier damage and increased permeability caused by pathogenic bacteria.

[0015] The application of the Lactobacillus reuteri N-FE-002 strain described in the present invention in improving the intestinal health of pets can enhance the expression of tight junction proteins in intestinal cells and reduce the expression of inflammatory cytokines, thereby improving the intestinal cell barrier damage and inflammatory response caused by pathogenic bacteria.

[0016] The invention provides a Lactobacillus reuteri N-FE-002 strain having high acid resistance and bile salt resistance characteristics: ① the growth rate can be maintained at more than 50% after being treated in MRS with pH 2.0 for 1 hour; ② the growth rate can be maintained at more than 70% after being treated in 0.1% ox bile salt-MRS for 1 hour.

[0017] The Lactobacillus reuteri N-FE-002 strain of the present invention has the characteristic of resistance to digestion by gastrointestinal fluid: the survival rate can be maintained at more than 20% after being digested by simulated gastrointestinal fluid for 5 hours.

[0018] The Lactobacillus reuteri N-FE-002 strain of the present invention has the performance of low production of bioamines, is sensitive to multiple antibiotics and has good safety.

[0019] Compared with the prior art, the Lactobacillus reuteri N-FE-002 strain and its application described in the present invention have the following advantages:

[0020] 1. The N-FE-002 strain comes from healthy kittens, has natural adaptability, and is easier to colonize and exert its effect in the pet's intestines.

[0021] 2. The N-FE-002 strain can significantly increase the expression of tight junction proteins in intestinal cells, reduce the expression of inflammatory factors, enhance intestinal barrier function, and improve intestinal health.

[0022] 3. Good anti-pathogen effect: This strain has a significant inhibitory effect on pathogens such as Shigella dysenteriae and Clostridium perfringens, and effectively prevents pathogenic bacteria from adhering to and invading intestinal cells.

[0023] 4. The N-FE-002 strain has the ability to produce a variety of enzymes, such as galactosidase, sucrase and amylase, which helps to improve the intestinal microecological environment, promote the growth of beneficial bacteria, and also help to decompose complex carbohydrates and sugars, improve the microbial balance in the intestine and promote intestinal health. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The accompanying drawings constituting a part of the present invention are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the accompanying drawings:

[0025] Figure 1 Phylogenetic tree of Lactobacillus reuteri N-FE-002 and related strains. The tree was constructed by maximum likelihood method based on 16S rDNA gene sequence and verified by 1000 bootstrap replications. The figure shows the relationship between Lactobacillus reuteri N-FE-002 and other Lactobacillus reuteri and congener strains obtained from NCBI database. The N-FE-002 strain formed a unique sub-branch, showing its unique genetic characteristics.

[0026] Figure 2 The microscopic diagram of Lactobacillus reuteri N-FE-002 described in the embodiment of the present invention is shown in Figure 1. The strain is Gram-positive after Gram staining and has a rod-shaped morphology.

[0027] Figure 3This is a schematic diagram of the inhibition zone of Lactobacillus reuteri N-FE-002 against pathogens described in the embodiments of the present invention. The figure shows the antibacterial effect of the N-FE-002 strain on Shigella dysenteriae and Clostridium perfringens, and the transparent area around each inhibition zone indicates a significant inhibitory effect on pathogens.

[0028] Figure 4 This is a schematic diagram of the adhesion of Lactobacillus reuteri N-FE-002 to Caco-2 cells described in the embodiments of the present invention. The figure shows the adhesion of the N-FE-002 strain on the surface of Caco-2 cells, showing its good cell adhesion ability, which helps it to colonize and function in the intestinal environment.

[0029] Figure 5 The figure shows the effect of Lactobacillus reuteri N-FE-002 on the expression of tight junction proteins in Caco-2 cells infected with Shigella dysenteriae. The figure shows the effect of different treatment groups on the expression of occludens, tight junction proteins ZO-1 and tight junction proteins Claudin-1. The results are expressed as mean ± standard deviation (SD), and significant differences are indicated by P (P<0.05 represents significant difference). The N-FE-002 strain significantly increased the expression of Occludin, ZO-1 and Claudin-1 (P<0.05), indicating that it plays a significant role in maintaining the integrity of the intestinal barrier.

[0030] Figure 6 The figure shows the effect of Lactobacillus reuteri N-FE-002 on inflammatory factors in Caco-2 cells infected with Shigella dysenteriae. The figure shows the effect of different treatment groups on the expression of TNF-α and IL-10. The results are expressed as mean ± standard deviation (SD), and significant differences are indicated by P (P<0.05 represents significant difference). The Lactobacillus reuteri N-FE-002 treatment group significantly reduced the level of cytokine TNF-α (P<0.05).

[0031] Figure 7 This is the utilization of different prebiotics by Lactobacillus reuteri N-FE-002 (growth curve).

[0032] Figure 8 This is the result of hemolytic determination of Lactobacillus reuteri N-FE-002. No hemolytic zone / ring is produced around the colonies on the Columbia blood agar plate, indicating that it is non-hemolytic. DETAILED DESCRIPTION

[0033] It should be noted that, in the absence of conflict, the embodiments of the present invention and the features in the embodiments may be combined with each other.

[0034] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the invention pertains. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein may also be used in the practice or testing of the present invention.

[0035] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0036] The present invention will be described in detail below with reference to the accompanying drawings and in conjunction with embodiments.

[0037] Example 1 Isolation and identification of strains

[0038] 1. Materials and Methods

[0039] 1. Reagents and drugs: De Man, Rogosa and Sharpe (MRS) broth, MRS agar medium, L-cysteine ​​hydrochloride (Lys), and Gram staining kit were purchased from Haibo Biotechnology (Qingdao, China); 0.9% sodium chloride injection (injection-grade saline) was purchased from Chenxin Pharmaceutical (Jining, China); bacterial culture dishes, bacterial shaking tubes, inoculation needles, etc. were purchased from Beekman Biotechnology (Changde, China).

[0040] 2. Collection, separation and purification of cat feces samples

[0041] ① Collection of fecal samples: Collect fresh feces of pet cats after free defecation into sterile centrifuge tubes and store them in a 4℃ transport box. Send them to the laboratory for processing within 1 hour.

[0042] ② Isolation and purification: Take about 1g of feces and add 49mL of injection-grade saline containing 0.04% Lys, shake and dissolve for 10 minutes; then use 0.04% Lys-saline to make 10-fold continuous gradient dilutions, spread on MRS agar plates, and place in an anaerobic incubator at 37°C for 48h (O 2 Concentration <5000ppm). Select a plate with appropriate concentration, pick single colonies with different colony morphology and color and streak them onto MRS plates, culture them anaerobically at 37℃ for 48h, repeat the separation and streaking for 6 times, inoculate the last purified single colony into MRS broth, culture them anaerobically at 37℃ for 24h, then store them in 15% sterile glycerol, freeze them at -80℃ and store them for later use.

[0043] 3. Identification of bacterial species: Inoculate the above-mentioned primary isolated bacteria into MRS broth at 1% to rejuvenate, then collect the bacteria by centrifugation and divide the bacteria equally into 3 centrifuge tubes (A, B, C). Perform Gram staining on tube A; add 1 mL of 3% hydrogen peroxide solution to tube B and observe the bubble production within 10 minutes (no bubble production is judged as catalase negative). Gram-positive and catalase-negative strains were identified by 16S rDNA sequencing (Genwi, Tianjin, China). The nucleic acid sequences were compared in the BLAST database.

[0044] 4. Construction of phylogenetic tree of strains: In order to clarify the taxonomic status of Lactobacillus reuteri N-FE-002 and its relationship with other related strains, we constructed a phylogenetic tree. The 16SrDNA gene sequence of the reference Lactobacillus reuteri was obtained from the NCBI database. Multiple sequence alignment (MSA) was performed using the Clustal Omega tool, and then the maximum likelihood method was used for analysis using IQ-TREE software, and 1000 bootstrap replicates were performed to ensure the stability and credibility of the results.

[0045] 2. Test results

[0046] From cat feces, 5 strains of Lactobacillus reuteri were obtained through separation and purification, Gram staining, catalase detection and bacterial 16S rDNA sequencing, as shown in Table 1. The results determined that the 16S rDNA sequence of Lactobacillus reuteri N-FE-002 had a homology of more than 99% with that of Limosilactobacillus reuteri.

[0047] Phylogenetic tree constructed based on 16S rDNA gene sequences ( Figure 1 )visible:

[0048] ① Lactobacillus reuteri N-FE-002 and Lactobacillus reuteri CFAC-19, which was also isolated from cat feces, clustered in the same large branch, but N-FE-002 formed an independent sub-branch, showing its unique genetic characteristics.

[0049] ② Lactobacillus reuteri N-FE-002 shows obvious distinction in genetic distance from other existing Lactobacillus reuteri obtained from the NCBI database, and is divided into two large branches. This indicates that Lactobacillus reuteri N-FE-002 of the present invention is genetically different from known strains to a certain extent. This branching structure further illustrates the unique genetic characteristics of N-FE-002 of the present invention.

[0050] Figure 2This is a microscopic image of Lactobacillus reuteri N-FE-002, which is Gram-positive and has a rod-shaped bacterial morphology. Lactobacillus reuteri N-FE-002 grows in a temperature range of 25 to 45°C and is facultatively anaerobic; it does not produce hemolysin and does not reduce nitrate.

[0051] The sugar fermentation spectrum determined that Lactobacillus reuteri N-FE-002 had the ability to utilize raffinose, sucrose, maltose, lactose, galactose and starch; and had the ability to produce galactosidase, sucrase, glucosidase and amylase.

[0052] The Lactobacillus reuteri N-FE-002 strain of the present invention was deposited on September 1, 2023 in the China General Microbiological Culture Collection Center (CGMCC) located at the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, China. Its microbial preservation number is CGMCC NO.28325, and the recommended classification name is: Lactobacillus reuteri (Limosilactobacillus reuteri).

[0053] Table 1 Information of 5 strains of Lactobacillus reuteri obtained from cat feces

[0054] Strain number Gram stain Bacterial morphology Colony morphology Catalase activity N-FE-002 G+ Rod Creamy / white Negative CFAC-15 G+ Rod Creamy / white Negative CFAC-25 G+ Rod Creamy / white Negative CFAC-19 G+ Rod Creamy / white Negative CFAC-14 G+ Rod Creamy / white Negative

[0055] Example 2 Acid and bile resistance test

[0056] 1. Materials and Methods

[0057] 1. Reagents and materials: Ox bile salt was purchased from Haibo Biotechnology (Qingdao, China); commercialized Pediococcus acidilactici strain (commercial P.ac) was purchased from a probiotic product on the market and used in the control experiment.

[0058] 2. Acid and bile resistance test: The above 5 strains of cat feces-derived Lactobacillus reuteri and commercial P.ac bacteria were resuspended in ultrapure water and divided into 50 μL bacterial solution / tube. Then, 1 mL of the corresponding treatment solution was added according to the grouping, treated at 37 ° C for 1 hour, centrifuged immediately and the supernatant was discarded, 10 mL of MRS broth was added, and cultured at 37 ° C. The OD value of the bacterial solution was read at 0 h and 4 h of culture, and the growth ratio and acid and bile resistance index were calculated. Each group was repeated 3 times. Statistical differences were analyzed by ANOVA analysis of variance and LSD post hoc test. P < 0.05 indicates a significant difference. The groups are as follows:

[0059] (1) Control group: normal group (MRS pH 7.2, 0% bile salt); negative control group (bacterial liquid was replaced by ultrapure water).

[0060] (2) Experimental group: Acid treatment group (MRS at pH 2.0, 0% bile salt); 0.2% bile salt treatment group (0.2% bile salt MRS, pH 7.2); 0.1% bile salt treatment group (0.1% bile salt MRS, pH 7.2).

[0061] Calculation formula:

[0062] Growth ratio (%) = (OD of experimental group 4h - OD of experimental group 0h ) / (OD of normal group 4h - OD of normal group 0h ) × 100%.

[0063] Acid and bile salt tolerance index (%) = Growth ratio 酸处理组 × 0.5 + (Growth ratio 0.2%胆盐处理组 + Growth ratio 0.1%胆盐处理组 ) × 0.25.

[0064] II. Test results

[0065] As shown in Table 2, commercial P.ac was completely inactivated after 1 h of treatment with MRS at pH 2.0 (growth ratio was 0%), while Lactobacillus mucosae N-FE-002 could maintain a growth of 52.2 ± 2% after 1 h of treatment with MRS at pH 2.0. This indicates that Lactobacillus mucosae N-FE-002 has strong acid tolerance and is higher than the other 4 co-isolated Lactobacillus mucosae strains (P < 0.05). Lactobacillus mucosae N-FE-002 has the highest acid and bile salt tolerance index, indicating that this strain has excellent acid and bile salt tolerance characteristics, which is beneficial to withstand gastrointestinal digestion and reach the intestine to play a role.

[0066] Table 2 Acid and bile salt tolerance of Lactobacillus mucosae

[0067]

[0068] Note: Significant difference *P < 0.05, **0.01 < P < 0.05, ***P < 0.01; # indicates that the significant results in the same column are all from the comparison with N-FE-002.

[0069] Example 3 Bacteriostatic test

[0070] I. Materials and methods

[0071] 1. Reagents and materials: Luria-Bertani (LB) broth, LB agar medium, thioglycollate broth and agar medium, and quadruple Oxford cups were purchased from Haibo Biotech (Qingdao, China).

[0072] 2. Bacteriostatic circle test: Two common pathogenic bacteria were selected as indicator bacteria, including Shigella dysenteriae BNCC339874 and Clostridium perfringens BNCC185933 (both purchased from Beina Biology). Shigella dysenteriae with a 0.5 McF McFarland concentration was inoculated at 1% into molten LB agar at 50 °C, thoroughly mixed and then poured onto plates; the 0.5 McF Clostridium perfringens solution was spread onto thioglycollate plates. Oxford cups were placed on the two prepared indicator bacteria plates, and 200 μL of the Lactobacillus mucosae N-FE-002 bacterial solution to be evaluated (5.7 McF) was added, and cultured for 24 h. The diameter of the bacteriostatic circle was measured using a bacteriostatic circle measuring instrument. MRS broth was added to the Oxford cups as a negative control. Each group was repeated 4 times.

[0073] II. Test results

[0074] Figure 3 The bacteriostatic circles of Lactobacillus mucosae N-FE-002 against two pathogenic bacteria are shown. As can be seen from Table 3, Lactobacillus mucosae N-FE-002 has inhibitory effects on both Shigella dysenteriae and Clostridium perfringens. Compared with the other two strains of Lactobacillus mucosae from cat feces with better performance, N-FE-002 has stronger inhibitory ability against Shigella dysenteriae and Clostridium perfringens (P < 0.05). Compared with commercial P.ac, N-FE-002 has stronger inhibitory ability against Clostridium perfringens (P < 0.05).

[0075] Table 3 Bacteriostatic circle diameters of Lactobacillus mucosae

[0076]

[0077] Note: Significant differences *P < 0.05, **0.01 < P < 0.05, ***P < 0.01; # indicates that the significant results in the same column are all from the comparison with N-FE-002.

[0078] Example 4 Simulated gastrointestinal digestion test

[0079] I. Materials and methods

[0080] 1. Reagents and materials

[0081] Preparation of simulated gastric juice: Pepsin was supplemented to 2000 U / mL and gastric lipase to 60 U / mL in artificial gastric juice (Beijing Leagene Biotechnology), with a pH of 3.0.

[0082] Preparation of simulated intestinal juice: 0.20% bile salt, pancreatic protease to 100 U / mL, pancreatic lipase to 2000 U / mL, and amylase to 200 U / mL were supplemented in artificial intestinal juice (Beijing Leagene Biotechnology), with a pH of 7.4.

[0083] 2. Simulated digestion test: Take 150μL of Lactobacillus reuteri N-FE-002 bacterial solution, add 3mL of simulated gastric juice, place in a 37℃ water bath shaker for digestion for 1-2h, then centrifuge and discard the supernatant, add 3mL of simulated small intestinal fluid, continue digestion for 1-3h, centrifuge after digestion, and use MRS plate to count live bacteria. The bacterial solution before digestion is used as a negative control (NC). The survival rate calculation formula is: survival rate (%) = live bacteria concentration after digestion / live bacteria concentration before digestion × 100%.

[0084] 2. Test results

[0085] As shown in Table 4, after 1 hour of gastric digestion and 2 hours of small intestinal digestion, the viable bacterial concentration of Lactobacillus reuteri N-FE-002 remained at 1.00E+09 CFU / mL (relative to 30.0% of the original activity). Under more extreme digestion conditions (2 hours of gastric digestion and 3 hours of small intestinal digestion), Lactobacillus reuteri N-FE-002 can still maintain a viable bacterial concentration of 7.00E+08 CFU / mL (relative to 21.0% of the original activity). This shows that the Lactobacillus reuteri N-FE-002 isolated by the present invention has excellent gastrointestinal digestion resistance.

[0086] Table 4 Survival rate of Lactobacillus reuteri N-FE-002 after simulated gastrointestinal digestion

[0087] Group Gastric digestion time (h) Intestinal digestion time (h) Live bacteria concentration (CFU / mL) Survival rate NC 0 0 3.33E+09 100.0% G1 1 1 1.57E+09 47.0% G2 1 2 1.00E+09 30.0% G3 1 3 8.00E+08 24.0% G4 2 1 1.07E+09 32.0% G5 2 2 9.00E+08 27.0% G6 2 3 7.00E+08 21.0%

[0088] Example 5 Intestinal epithelial cell adhesion

[0089] 1. Materials and Methods

[0090] 1. Reagents and materials: Human colorectal adenocarcinoma cells (Caco-2 cells, correctly identified by STR) were provided by Pronocell Life Science Co., Ltd. (Wuhan, China) and used to construct the intestinal epithelial cell model.

[0091] 2. Cell culture and intestinal epithelial model construction: Caco-2 cells (20 to 50 generations) were revived in 20% FBS-DMEM medium and subcultured once every 3 days for 3 times. Subsequently, 15% FBS-DMEM medium was used to inoculate in a 10 cm culture dish and cultured continuously for 14 days. Alkaline phosphatase activity was measured once every 7 days. If the change factor was greater than 2, it indicated that Caco-2 cells had differentiated into intestinal epithelial cell-like characteristics. The differentiated Caco-2 cells were cultured at 2×10 5 cells / well, inoculated into a 6-well plate or a 6-well plate with a cell slide, and cultured for 5 days to construct an intestinal epithelial cell model.

[0092] 3. Adhesion test

[0093] Adhesion index test: Lactobacillus reuteri N-FE-002 was centrifuged and resuspended in DMEM medium with a bacterial concentration of 3.75×10 7 CFU / mL. Wash the cultured Caco-2 cell 6-well plate 3 times with warm PBS. Then add 2mL of N-FE-002 bacterial solution, culture for 4h, and wash 5 times with warm PBS for 1min each time to remove non-adherent bacteria. Immediately add 0.25% EDTA-trypsin to digest for 3min, collect the digestion solution, and count the colonies on MRS plate. The adhesion index calculation formula is: Adhesion index = total number of adherent colonies (CFU) / total number of cells (Cells).

[0094] Adhesion rate test: Similar to the adhesion index test, the difference is that the N-FE-002 bacterial solution is added to the 6-well plate of the Caco-2 cell slide, incubated and washed, and the slide is fixed with 4% paraformaldehyde for 15 minutes. Then the slide is Gram-stained, and the total number of cells and the number of cells with bacteria adhered in 8 fields of view are randomly observed under an upright microscope. The adhesion rate calculation formula is: Adhesion rate (%) = number of cells with bacteria adhered / total number of cells × 100%.

[0095] 2. Test results

[0096] Figure 4 The microscopic picture of Lactobacillus reuteri N-FE-002 adhering to Caco-2 cells shows that the adhesion rate reaches 93.7±6.3%. As shown in Table 5, the adhesion index of Lactobacillus reuteri N-FE-002 to Caco-2 cells is 21.9±4.3 CFU / cell. This shows that Lactobacillus reuteri N-FE-002 has efficient adhesion properties to the intestinal epithelium, which is conducive to intestinal colonization.

[0097] Table 5 Adhesion of Lactobacillus reuteri N-FE-002 to Caco-2 cells

[0098]

[0099] Example 6 Anti-pathogenic bacteria adhesion test

[0100] 1. Test Method

[0101] Differentiated Caco-2 cells were cultured at 2×10 5 cells / well, inoculated into 6-well plates and cultured for 5 days to construct an intestinal epithelial cell model. 5 CFU / mL Shigella dysenteriae was used as the indicator pathogen. Lactobacillus reuteri N-FE-002 was used at a concentration of 1.875×10 7CFU / mL. Three treatment methods were selected to evaluate the ability of Lactobacillus reuteri N-FE-002 to resist the adhesion of pathogenic bacteria. The experimental groups are shown in Table 6. When lactic acid bacteria were not added, DMEM basal medium was used instead. After treatment, the cells were washed 3 times with warm HBSS, each time for 1 min. Trypsin was added for digestion for 3 min, the digestion fluid was collected, and the colonies of adhered Shigella were counted using selective Salmonella Shigella (SS) agar plates to calculate the adhesion index.

[0102] Table 6 Anti-pathogenic bacteria adhesion results of Lactobacillus reuteri N-FE-002

[0103]

[0104] 2. Test results

[0105] As shown in Table 6, in the lactic acid bacteria simultaneous treatment group, the adhesion inhibition rate of N-FE-002 to Shigella reached 51.7%. In the lactic acid bacteria pre-treatment group, the adhesion inhibition rate of N-FE-002 to Shigella reached 24.3%. This shows that Lactobacillus reuteri N-FE-002 inhibits and reduces the adhesion of pathogenic bacteria to intestinal epithelial cells through competition and occupancy mechanisms. These results confirm that Lactobacillus reuteri N-FE-002 of the present invention not only has the ability to inhibit the reproduction of pathogenic bacteria, but also has the ability to prevent the adhesion of pathogenic bacteria.

[0106] Example 7 Cell barrier integrity and permeability test

[0107] 1. Test methods

[0108] 1. Construction of intestinal epithelial monolayer cell model: Caco-2 cells were cultured at 2×10 5 cells / well, inoculated into the upper chamber of a 6-well Transwell plate, and supplemented with 15% FBS-DMEM medium in the lower chamber. The medium was changed once every 2 days, and the transepithelial electrical resistance (TREE) value was measured using a resistance meter. The culture was continued for 14 days. The TREE value of the monolayer cell model used in the present invention reached 656Ω·cm at 14 days. 2 The above results indicate that the model is well-integrated; the ratio of alkaline phosphatase activity between the upper and lower chambers is greater than 2.5, indicating that the cell membrane of the upper chamber is fully polarized and has intestinal epithelial cell-like characteristics. Therefore, the intestinal epithelial monolayer cell model has been successfully constructed and can be used for subsequent experiments.

[0109] 2. Permeability test: The test was carried out in the Transwell model constructed above. The grouping and treatment methods are shown in Table 7. A negative control group (without any treatment) was added, and each group was repeated 3 times. After the grouping treatment was completed, the upper and lower chambers of the Transwell were washed 3 times with warm HBSS, 2 mL of 10 mg / mL phenol red solution was added to the upper chamber, and 2.5 mL of HBSS was added to the lower chamber. After being placed at 37°C for 2 hours, 0.5 mL of the lower chamber liquid of each group was collected, 1 mL of 10 mol / L NaOH was added, and the absorbance was measured at a wavelength of 560 nm to obtain the permeated phenol red concentration. The apparent permeability coefficient (Papp) of phenol red is calculated as follows: Papp = (dQ / dt) / (AC0):

[0110] Where dQ / dt is the transport amount of phenol red per unit time (μg / s); A is the membrane area (4.67cm 2 ); C0 is the initial phenol red concentration (μg / mL).

[0111] Permeability (%) = (Papp 各处理组 -Papp 阴性对照组 ) / Papp 阴性对照组 × 100%. The permeability of the negative control group was set to 0%.

[0112] Permeation inhibition rate (%) = (permeability 阳性对照组 -Permeability N-FE-002组 ) / Permeability 阳性对照组 ×100%.

[0113] 3. Transepithelial electrical resistance test and barrier integrity assessment: The test was conducted in the Transwell model constructed above, and the grouping and treatment methods are shown in Table 7. The TERR values ​​of each group before and after treatment were measured and the TERR difference was calculated to evaluate the cell barrier integrity rate.

[0114] TERR value (Ω·cm 2 )=(Ω-Ω 0 )×S

[0115] Where, Ω is the measured transmembrane resistance, Ω 0 is the resistance of the cell-free pore, S is the membrane area (4.67 cm 2 ).

[0116] TERR difference (Ω·cm 2 )=TERR value 处理后 -TERR value 处理前 .

[0117] Barrier integrity rate (%) = (TERR difference 处理组 / TERR difference 阴性对照组)×100%. The barrier integrity rate of the negative control group was set as 100%.

[0118] 2. Test results

[0119] As shown in Table 7, under the three treatment methods, the positive control group (Shigella treatment alone) caused an increase in the transmembrane permeability of phenol red, which indicates that pathogenic bacteria induce intestinal cell barrier damage and increased permeability. Compared with the positive control group, the permeability of phenol red was significantly reduced under the simultaneous treatment and pretreatment of Lactobacillus reuteri N-FE-002, and the permeability inhibition rate reached 32.8% and 32.1%, respectively. The permeability inhibition rate of the lactic acid bacteria simultaneous treatment group was the largest, indicating that Lactobacillus reuteri N-FE-002 mainly resisted pathogenic bacteria through a competitive mechanism, which was consistent with the results of the anti-adhesion test.

[0120] The change in TEER value can reflect the integrity of the intestinal barrier. As shown in Table 8, under the three treatment methods, the positive control group (Shigella treated alone) caused a decrease in the integrity of the cell barrier, which indicates that the pathogenic bacteria caused damage to the intestinal cell barrier or a decrease in function. When the Lactobacillus reuteri N-FE-002 of the present invention was used for simultaneous treatment, pre-treatment or post-treatment, the integrity of the cell barrier was significantly enhanced. The recovery rates of barrier damage caused by Shigella reached 227.3%, 117.1% and 22.6% respectively.

[0121] These results confirm that Lactobacillus reuteri N-FE-002 can effectively alleviate the intestinal cell barrier damage and increased permeability caused by pathogenic bacteria, and enhance the integrity of the intestinal barrier.

[0122] Table 7 Effect of Lactobacillus reuteri N-FE-002 on intestinal barrier permeability

[0123]

[0124]

[0125] Table 8 Effect of Lactobacillus reuteri N-FE-002 on intestinal barrier integrity

[0126]

[0127] Example 8 Tight junction protein assay

[0128] 1. Test methods

[0129] Differentiated Caco-2 cells were cultured at 2×10 5 cells / well, inoculated into 6-well plates, and cultured for 5 days to construct an intestinal epithelial cell model. The cells were washed 3 times with warm HBSS, and 2 mL of treatment solution was added according to the grouping, and incubated at 37°C for 3 hours. The groups were:

[0130] ① Negative control group (DMEM);

[0131] ② Lactobacillus reuteri N-FE-002 group (concentration of about 1.875×10 7 CFU / mL);

[0132] ③Shigella group (concentration is about 7.5×10 5 CFU / mL);

[0133] ④ Lactobacillus reuteri N-FE-002 + Shigella group (concentrations were approximately 3.75×10 7 CFU / mL and 1.5×10 6 CFU / mL).

[0134] After treatment, remove the culture medium, place the 6-well plate on ice, add 200 μL of RIPA lysis buffer (with protease phosphatase inhibitors) to each well, shake the plate to mix thoroughly, and let it stand for 15 minutes. TM BCA protein detection kit (Thermo Fisher Scientific) was used for total protein quantification. ELISA (Shanghai Enzyme-Linked) was used for quantitative detection of occludin, claudin-1 and ZO-1.

[0135] 2. Test results

[0136] like Figure 5 As shown in the figure, compared with the negative control group, Lactobacillus reuteri N-FE-002 alone significantly increased the expression of occlusive protein Occludin, tight junction protein Claudin-1 and tight junction protein ZO-1 (P<0.05). Shigella did not have this effect. Compared with the Shigella group, the expression of occlusive protein Occludin and tight junction protein Claudin-1 in the group supplemented with Lactobacillus reuteri N-FE-002 was significantly increased. These data indicate that Lactobacillus reuteri N-FE-002 has a significant effect on promoting the expression of tight junction proteins in intestinal epithelial cells, thereby improving the integrity and stability of the intestinal barrier.

[0137] Example 9 Cytokine Assay

[0138] 1. Test method: ELISA (Shanghai ELISA) was used to detect the content of tumor necrosis factor-α (TNF-α) and interleukin IL-10 in the above cell lysate.

[0139] 2. Test results

[0140] like Figure 6As shown, compared with the negative control group, Shigella treatment significantly enhanced TNF-α expression, indicating that pathogenic bacteria triggered inflammatory responses and immune stress in intestinal cells. Compared with the Shigella group, supplementation with Lactobacillus reuteri N-FE-002 significantly reduced TNF-α expression, but there was no significant change in the anti-inflammatory cytokine IL-10. This suggests that Lactobacillus reuteri N-FE-002 has the effect of inhibiting inflammatory responses, thereby maintaining intestinal barrier homeostasis.

[0141] Example 10 Transcriptome Sequencing

[0142] 1. Test methods

[0143] To further confirm the effect of Lactobacillus reuteri N-FE-002, transcriptome sequencing was performed on intestinal Caco-2 cells treated with N-FE-002.

[0144] ① Negative control group (DMEM);

[0145] ② Lactobacillus reuteri N-FE-002 group (concentration of about 1.875×10 7 CFU / mL);

[0146] After the cells were treated, the cell supernatant was discarded, and then the 6-well plate was placed on ice. 1 mL of Trizol total RNA extract was added to each well, the well plate was shaken to mix thoroughly, and the cells were collected into centrifuge tubes, immediately frozen in liquid nitrogen, and sent to a sequencing company (Genwizhi) for transcriptome sequencing. Gene annotations were obtained by comparing with the reference genome. Gene expression was calculated using Cuffdiff software (v2.2.1). Differentially expressed genes were screened according to a change factor greater than 2 and P < 0.05. Differential gene enrichment annotations were performed using the Gene Ontology database, KEGG database, etc., and the enrichment and biological functions of differentially expressed genes between groups in biological processes, biochemical metabolic pathways, and signal transduction pathways were analyzed and compared.

[0147] 2. Test results

[0148] ① Enhance tight connections

[0149] As shown in Table 9, compared with the negative control, treatment with Lactobacillus reuteri N-FE-002 significantly promoted the expression of tight junction-related genes SCRIB and DLG1. SCRIB is related to processes such as cell polarity, cell movement, and cell proliferation. Its upregulation may enhance cell migration ability and cell-cell interactions. DLG1 is mainly related to cell polarity and cell proliferation. It also plays a key role in maintaining the stability of the cell surface. The upregulation of DLG1 may strengthen cell-to-cell connections.

[0150] ②Promote cell proliferation through the Hedgehog signaling pathway

[0151] As shown in Table 9, compared with the negative control, Lactobacillus reuteri N-FE-002 treatment was significantly enriched in the Hedgehog signaling pathway, among which genes such as GPR161 and PRKACB were downregulated, and genes such as FBXW11 and CSNK1G3 were upregulated, which was beneficial to cell proliferation, survival or differentiation.

[0152] Table 9 Significantly differentially expressed genes and biological pathways determined based on transcriptome sequencing

[0153]

[0154] Example 11 Prebiotic Utilization Test

[0155] 1. Test methods

[0156] Sugar-free MRS broth was selected to evaluate the growth of Lactobacillus reuteri N-FE-002 under different prebiotics as the sole carbon source. Fructooligosaccharides, galacto-oligosaccharides, isomaltooligosaccharides, and manno-oligosaccharides were filtered and sterilized and added to MRS at a final concentration of 2%. Sugar-free MRS was used as a blank control, and glucose was used as a positive control. Lactobacillus reuteri N-FE-002 was inoculated into culture media with different carbon sources at 1% and then cultured at 37°C for 24 hours. The absorbance of the fermentation broth at 600nm was then measured every 2 or 4 hours. The growth curve was drawn with time as the abscissa and the absorbance as the ordinate.

[0157] 2. Experimental Results

[0158] From the experimental results ( Figure 7 ) It can be concluded that the growth of Lactobacillus reuteri N-FE-002 is most significant under the conditions of galacto-oligosaccharides and glucose, showing a strong proliferation ability. The second is isomaltooligosaccharide. In contrast, under sugar-free and oligofructose conditions, the growth of the strain is limited. The experimental results show that galacto-oligosaccharides and isomaltooligosaccharides are preferred prebiotics for Lactobacillus reuteri N-FE-002, which help to enhance the proliferation effect of Lactobacillus reuteri N-FE-002.

[0159] Example 12 Safety Test

[0160] 1. Hemolytic test

[0161] 1. Test method: Spread the bacterial solution of Lactobacillus reuteri N-FE-002 on Columbia blood agar plates, culture them at 37°C for 48 hours, and observe the hemolysis of blood cells around the colonies.

[0162] 2. Experimental results: Figure 8As shown, there is no hemolytic zone around the colonies of Lactobacillus reuteri N-FE-002, indicating that the hemolytic type of Lactobacillus reuteri N-FE-002 is non-hemolytic and has good safety.

[0163] 2. Biogenic Amine Test

[0164] 1. Experimental method: Ornithine (putrescine precursor), lysine (cadaverine precursor), histidine (histamine precursor), and tyrosine (tyramine precursor) were added to sugar-free MRS broth, and the pH was adjusted to 5.5. Lactobacillus reuteri N-FE-002 was added to different amino acid MRS at a 1% inoculation rate, a commercial strain of Pediococcus acidilactici (P.ac) was used as a negative control, and a pathogenic bacterium (Salmonella enteritidis) that produces high amounts of bioamines was used as a positive control. All groups were cultured at 37°C for 48 hours, and the fermentation broth supernatant was collected. The four biogenic amines were quantitatively detected using a high-performance liquid chromatograph (Thermo U3000).

[0165] 2. Test results: As can be seen from Table 10, the level of biogenic amines produced by Lactobacillus reuteri N-FE-002 in different amino acid environments is low, which is comparable to the production of commercial Pediococcus acidilactici (P.ac). In particular, compared with the positive control Salmonella, the amount of biogenic amines produced by N-FE-002 is significantly lower. This indicates that N-FE-002 does not have the ability to produce high toxic biogenic amines and has good safety.

[0166] Table 10 Biogenic amine production by Lactobacillus reuteri N-FE-002 in different amino acid environments

[0167]

[0168] 3. Antimicrobial Susceptibility Testing

[0169] 1. Test method: The antimicrobial susceptibility test refers to the CLSI "Antimicrobial Susceptibility Test Operation Standard 2023" and the Ministry of Agriculture and Rural Affairs "Guidelines for Identification of Strains and Safety Evaluation of Direct-fed Microorganisms and Fermentation Products Production Strains

[2021] No. 43". MRS agar (pH 6.5) was used as the culture medium, and the incubation time was 24h. The sensitivity test was performed using the E-TEST method. 2. Results: It can be seen that Lactobacillus reuteri N-FE-002 showed good sensitivity to a variety of commonly used antimicrobial drugs. Specifically, Lactobacillus reuteri N-FE-002 is sensitive to ampicillin, gentamicin, streptomycin, erythromycin, clindamycin, tetracycline and chloramphenicol (S). It is worth noting that Lactobacillus genus shows natural resistance to vancomycin (R), with a MIC value greater than 256 mg / L.

[0170] Table 11 The sensitivity results of Lactobacillus reuteri N-FE-002 to antimicrobial drugs

[0171] Antimicrobial drugs Reference Cutoff(mg / L) N-FE-001MIC(mg / L) Identification results Ampicillin (Amp) 2 0.75 S Vancomycin (Van) n.r. >256 R Gentamycin (Gen) 8 6 S Kanamycin (Kana) 64 64 S Streptomycin (Str) 64 64 S Erythromycin (Ery) 1 1 S Clindamycin (Clin) 4 0.38 S Tetracycline (Tet) 32 16 S Chloramphenicol (Chl) 8 8 S

[0172] Note: S stands for sensitive; R stands for resistant.

[0173] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A Lactobacillus reuteri strain, Features: The name of the strain is: N-FE-002. It was deposited on September 1, 2023 in the China General Microbiological Culture Collection Center (CGMCC) located at the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, China. Its microbial preservation number is CGMCC NO.28325, and its classification name is: Limosilactobacillus reuteri.

2. The use of the Lactobacillus reuteri strain according to claim 1, Features This Lactobacillus reuteri strain is used to improve intestinal health in pets.

3. The use of the Lactobacillus reuteri strain according to claim 1, Features The Lactobacillus reuteri strain is used to inhibit pathogenic bacteria such as Shigella dysenteriae and Clostridium perfringens.

4. The use of the Lactobacillus reuteri strain according to claim 1, Features The Lactobacillus reuteri strain is used to resist the adhesion of pathogenic bacteria and repair intestinal barrier damage.

5. The use of the Lactobacillus reuteri strain according to claim 1, Features The Lactobacillus reuteri strain is used to promote the expression of tight junction proteins in intestinal cells and reduce the expression of pro-inflammatory cytokines, thereby improving intestinal barrier function.

6. The use of the Lactobacillus reuteri strain according to claim 1, Features This Lactobacillus reuteri strain produces galactosidase, sucrase and amylase to improve the intestinal microecological environment of pets.

7. The use of the Lactobacillus reuteri strain according to claims 2-6, Features The Lactobacillus reuteri strain is prepared in the form of food, health care products, feed additives and medicines to improve the intestinal health of pets.

8. The use of the Lactobacillus reuteri strain according to claim 7, Features The food, health product, feed additive and medicine further contain one or more of galacto-oligosaccharide or isomalto-oligosaccharide to enhance the effect of probiotics.

Citation Information

Patent Citations

  • Lactobacillus reuteri AUc2301 with anti-inflammatory and immunoregulation functions and application of lactobacillus reuteri AUc2301

    CN117625463A

  • Lactobacillus reuteri GOLDGUT-LR99 and application thereof

    CN117821327A

  • Lactobacillus reuteri BN01 for repairing gastrointestinal mucosa injury and metagen thereof

    CN117866854A

  • Lactobacillus reuteri Glory LR15 composition with immunity improving function and preparation method of lactobacillus reuteri Glory LR15 composition

    CN117981875A

  • Lactobacillus reuteri for producing conjugated linoleic acid by metabolizing linoleic acid and having function of enhancing intestinal barrier and application of lactobacillus reuteri

    CN118222432A

Cited By

  • Lactobacillus reuteri and application thereof

    CN120718806A

  • Lactobacillus reuteri and application thereof in enhancing intestinal barrier

    CN120966685A

  • Lactobacillus reuteri FMZ07 and application thereof in depression resistance and intestinal flora improvement

    CN121991862A